{"id":82933,"date":"2026-06-17T08:16:07","date_gmt":"2026-06-17T12:16:07","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/jazz-pharmaceuticals-signs-cancer-antibody-deal-worth-up-to-876-million\/"},"modified":"2026-06-17T08:16:07","modified_gmt":"2026-06-17T12:16:07","slug":"jazz-pharmaceuticals-signs-cancer-antibody-deal-worth-up-to-876-million","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/jazz-pharmaceuticals-signs-cancer-antibody-deal-worth-up-to-876-million\/","title":{"rendered":"Jazz Pharmaceuticals Signs Cancer Antibody Deal Worth Up to $876 Million"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

Jazz Pharmaceuticals announced Wednesday that it has entered into a research collaboration and licensing agreement with AbCellera, a Canadian biotechnology company, to develop T-cell engaging multispecific antibodies aimed at treating cancer.<\/p>

Under the terms of the agreement, AbCellera will receive $56 million upfront to cover two initial research programs set to launch within the next 12 months. An additional $28 million will be paid when a third program gets underway. Beyond those initial payments, AbCellera stands to collect up to $792 million per program in option fees and milestone payments, depending on how Jazz chooses to advance the resulting drug candidates. The company would also earn tiered royalties on any future product sales.<\/p>

The collaboration will center on developing therapies for gastrointestinal cancers and other solid tumors. Jazz described the effort as consistent with its broader strategy to grow its oncology business while continuing to support its rare disease operations.<\/p>

AbCellera will take the lead on early-stage discovery work, drawing on its proprietary antibody development platform. If Jazz exercises its options, it would gain exclusive worldwide rights to develop and bring any resulting treatments to market.<\/p>

The two companies may also choose to broaden the partnership to include as many as two additional research programs. AbCellera could also play a role in later stages of development, potentially assisting with studies required to file investigational new drug applications and with manufacturing clinical supply.<\/p>

T-cell engaging antibodies work by directing the body’s own immune cells \u2014 specifically T-cells \u2014 to identify and attack cancer cells. This approach has gained growing attention in the medical research community as a potential strategy for tackling tumors that are difficult to treat with conventional therapies.<\/p>","protected":false},"excerpt":{"rendered":"

Jazz Pharmaceuticals has entered into a research and licensing agreement with Canadian biotech company AbCellera to develop a new class of cancer-fighting antibodies. The deal could be worth as much as $876 million in total payments. The partnership will focus on developing treatments for gastrointestinal cancers and other difficult-to-treat solid tumors.<\/p>\n","protected":false},"author":4,"featured_media":82932,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[834],"tags":[],"class_list":["post-82933","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781698566688.png?fit=1920%2C1080&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-lzD","jetpack-related-posts":[{"id":41109,"url":"https:\/\/tvdelmarva.com\/wp\/french-pharma-giant-partners-with-kali-therapeutics-for-autoimmune-drug-development\/","url_meta":{"origin":82933,"position":0},"title":"French Pharma Giant Partners with Kali Therapeutics for Autoimmune Drug Development","author":"Admin","date":"March 23, 2026","format":false,"excerpt":"Kali Therapeutics announced a major licensing partnership with French pharmaceutical company Sanofi to advance development of an experimental autoimmune disease treatment. The deal includes $180 million in initial payments and potential milestone payments reaching $1.05 billion.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774268567857.jpg?fit=450%2C307&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":80596,"url":"https:\/\/tvdelmarva.com\/wp\/jazz-pharmaceuticals-cancer-treatment-falls-short-in-clinical-trial\/","url_meta":{"origin":82933,"position":1},"title":"Jazz Pharmaceuticals Cancer Treatment Falls Short in Clinical Trial","author":"Admin","date":"June 12, 2026","format":false,"excerpt":"A lung cancer medication from Jazz Pharmaceuticals did not demonstrate improved patient survival rates in a major clinical study. The disappointing results could affect the drug's current regulatory approval status with federal health authorities.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781270713324.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781270713324.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781270713324.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781270713324.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1781270713324.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":65359,"url":"https:\/\/tvdelmarva.com\/wp\/delaware-pharmaceutical-company-secures-rights-to-new-breast-cancer-treatment\/","url_meta":{"origin":82933,"position":2},"title":"Delaware Pharmaceutical Company Secures Rights to New Breast Cancer Treatment","author":"Admin","date":"May 12, 2026","format":false,"excerpt":"Rigel Pharmaceuticals announced Tuesday it has acquired worldwide licensing rights to a newly approved breast cancer medication developed by Pfizer and Arvinas. The company will pay $85 million initially and could pay up to $320 million more based on future milestones.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778591181637.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778591181637.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778591181637.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778591181637.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778591181637.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":44071,"url":"https:\/\/tvdelmarva.com\/wp\/eli-lilly-partners-with-ai-company-in-2-billion-diabetes-drug-deal\/","url_meta":{"origin":82933,"position":3},"title":"Eli Lilly Partners with AI Company in $2 Billion Diabetes Drug Deal","author":"Admin","date":"March 29, 2026","format":false,"excerpt":"Pharmaceutical giant Eli Lilly is reportedly entering a massive $2 billion partnership with Hong Kong-based Insilico Medicine to develop diabetes treatments using artificial intelligence. The agreement includes $115 million upfront with additional payments tied to regulatory approvals and sales targets.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774786876701.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":68724,"url":"https:\/\/tvdelmarva.com\/wp\/swedish-biotech-secures-134m-european-licensing-deal-for-kidney-drug\/","url_meta":{"origin":82933,"position":4},"title":"Swedish Biotech Secures $134M European Licensing Deal for Kidney Drug","author":"Admin","date":"May 19, 2026","format":false,"excerpt":"Hansa Biopharma announced a major licensing agreement worth up to $134 million with SERB Pharmaceuticals for its kidney transplant medication Idefirix across European markets. The deal strengthens the Swedish company's financial position ahead of a potential U.S. drug approval decision expected in December.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":59679,"url":"https:\/\/tvdelmarva.com\/wp\/cannabis-drug-companies-see-new-investment-opportunities-after-federal-reclassification\/","url_meta":{"origin":82933,"position":5},"title":"Cannabis Drug Companies See New Investment Opportunities After Federal Reclassification","author":"Admin","date":"April 30, 2026","format":false,"excerpt":"Pharmaceutical companies developing marijuana-based medications say recent federal reclassification changes could open doors to private investment and public stock offerings. The shift from Schedule I to Schedule III status is expected to reduce stigma and attract mainstream investors who previously avoided the cannabis sector.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1777544670358.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/82933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=82933"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/82933\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/82932"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=82933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=82933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=82933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}